Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
source: pixabay.com

Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients

According to a story from mdmag.com, a recent study that was presented at the 2019 meeting of the American Society of Clinical Oncology has demonstrated the potential of a two…

Continue Reading Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Free-Photos / Pixabay

Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

According to a story from Acrofan, the biopharmaceutical company SpringWorks Therapeutics, Inc. has recently announced the that company's experimental product candidate PD-0325901 has earned Fast Track designation from the US…

Continue Reading Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

A recent study published in PLOS Biology has shown a promising new vulnerability within human viruses which could lead to the development of a new antiviral drug. This study was…

Continue Reading Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU

Transfusion-Dependent β-Thalassemia (TDT) Transfusion-dependent β-thalassemia (TDT) is a rare disease that is caused by a mutated β-globin gene. This mutation causes the amount of hemoglobin in the body to be…

Continue Reading ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU